- Nanocap pharma Pulmatrix, Inc. ( NASDAQ: PULM ) dropped ~18% in the morning hours Wednesday after announcing topline results from a Phase 1 trial for PUR3100, an orally inhaled dry powder formulation of dihydroergotamine (DHE) targeting acute migraine.
- The Australia-based study involving 26 healthy subjects was designed to evaluate the impact of three doses of PUR3100 with an intravenous (IV) placebo against a single dose of IV DHE (DHE mesylate injection) with inhaled placebo.
- According to early results, PUR3100 was well-tolerated, leading to fewer incidences of nausea among participants who received PUR3100 than those in the IV DHE group.
- Explaining the pharmacokinetic findings from the rial, Margaret Wasilewski, the medical chief of Pulmatrix ( PULM ), said: "PUR3100 demonstrated a Cmax in the target range for systemic exposure at all doses and higher than the published Cmax data for all other non-IV DHE products."
- The investigators are currently reviewing the dose selection for a Phase 2 trial which the company intends to discuss with the FDA in H1 2023.
- In July, Pulmatrix ( PULM ) announced the dosing initiation in the trial expecting to disclose its data in Q4 2022.
For further details see:
Pulmatrix drops 18% after releasing early data for inhaled migraine therapy